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HISTORY
•75 year-old woman, history of anxiety and a right Colles fracture after a fall, treated non-surgically.
•Presented with progressive ambulatory dysfunction, rigidity, and frequent falls over 3 years.
•Often becomes stiff when startled or scared; had anxiety related to fear of falling.
•Diagnosed with anti-GAD negative Stiff-Person Syndrome (SPS) 4 months before rehab admission.
PHYSICAL EXAMINATION
•Admitted to acute rehabilitation at the maximal assistance level for transfers and toileting, and
moderate assistance level for grooming and ambulation with a platform walker. 
•Exam at admission: intact strength without focal neurologic deficit with the exception of notable axial 
and limb rigidity, Modified Ashworth Score of 3 in all limbs.
TREATMENTS
PHARMOCOLOGIC
•Prior to admission, she demonstrated clinical improvement of rigidity with diazepam, but only tolerated 
1mg qAM and 2mg qPM; higher doses caused sedation.
•Addition of Baclofen caused sedation and hypotension, which limited dosing to 20mg TID.
•Addition of Dantrolene, titrated to 50mg QID, reduced rigidity and increased function.
•A dose-dependent relationship to function was noted: when the dose was reduced to 25mg QID to 
reduce risk of hepatotoxicity, function declined as rigidity increased, and this change was reversed 
when the dose was increased again.
THERAPIES
Physical Therapy- strength training, balance, endurance, range of motion exercises.
Occupational Therapy- activities of daily living, compensatory skills, range of motion exercises.
Rehabilitation Psychology- education and counseling focused on facilitating adjustment to the medical 
and psychosocial impacts of SPS, including management of anxiety and depression.
RESULTS
•She progressed to supervision for grooming, moderate assistance for transfers and toileting, and 
minimal assistance for ambulation.
•Anxiety and depression were improved with psychological counseling, buspirone, and paroxetine.
•Improvement of Modified Ashworth Score from 3 to 1-2 in all limbs with dantrolene.
Figure 1: Gordon Clinical Diagnostic Criteria for 
Stiff-Person Syndrome
•Stiff-Person Syndrome (SPS) is a rare, progressive disorder characterized by rigidity, caused by 
deficient GABA utilization, that can severely limit quality of life.
•GABA agonists are the current primary treatment, but central side effects (sedation, hypotension) 
limit dosing, especially in the elderly who have a high falls risk.
•Dantrolene, a peripherally-acting agent, lacks significant central side effects. 
•Although the dantrolene does not fit the GABAergic mechanism of SPS, its use in this acute 
rehabilitation setting reduced rigidity and improved functional performance, thus reducing falls risk.
•This case demonstrates that dantrolene is a useful alternative treatment for rigidity in SPS.
•Further research is needed to determine if the improvement with dantrolene for SPS is reproducible 
with quantifiable improvement in outcome.
Figure 2: Pathogenic Mechanisms in Stiff-Person Syndrome
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CASE REPORT
Setting: University hospital-based acute rehabilitation.  
Patient: 75-year-old woman with Stiff-Person Syndrome (SPS) with a recent fall and Colles fracture. 
Case Description: Four months prior to admission, the patient was diagnosed with SPS, negative for 
anti-GAD antibodies.  Diagnosis was based on a 3-year history of progressive rigidity leading to frequent 
falls and fractures.  Anxiety and fear of falling limited her mobility, and she sustained a sacral pressure 
ulcer during acute hospitalization.  On admission, history was remarkable for unsteady gait and muscle 
cramps exacerbated when startled or excited.  Examination was remarkable for rigidity in her axial and 
limb muscles.  She presented at the maximal assist level for transfers and toileting and moderate assist 
level for grooming and ambulation using a platform walker (right arm in cast).  She was unable to tolerate 
titration of diazepam due to sedation, or baclofen due to hypotension.  
Results: During acute rehabilitation, rigidity was treated with titration of dantrolene (from 25 to 50 mg four 
times daily) in addition to maximal tolerated doses of diazepam (1 mg qAM/2 mg qPM) and baclofen 
(20mg TID).  The addition of dantrolene reduced rigidity and improved range of motion, both subjectively 
per patient and objectively by exam.  Functional gains stalled with dose decrease and resumed with dose 
increase.  She had pronounced gains in grooming to the supervision level, modest gains in transfers and 
toileting to the moderate assist level, but remained at the moderate assist level for ambulation.  Progress 
was limited due to a change to non-weight bearing status of her right arm.  Anxiety and depression were 
improved with buspirone, paroxetine, and psychological counseling.   
Discussion: SPS results in significant activity of daily life and ambulatory dysfunction as exemplified by 
her pressure ulcer and multiple falls.  Although GABA agonists are the preferred treatment for SPS, the 
adverse effects of high doses can increase the risk of falls.  Dantrolene reduced muscle rigidity and 
improved function without sedative or hypotensive effects.  
Conclusion: Dantrolene is a useful additional treatment for SPS rigidity.
1. Prodrome of episodic aching stiffness of axial muscles
2. Progression to include stiffness of proximal limbs
3. Painful spasms elicited by triggers
4. Increased lumbar lordosis
5. Normal sensation, motor function and intellect
6. Response to benzodiazepines
DIAGNOSIS
•Stiff-Person Syndrome (SPS), also known as Stiff-Man Syndrome, is a rare neuromuscular 
disorder characterized by rigidity; identified by Moersch and Woltman in 1956.
•Diagnostic criteria, still in use today, were first set by Gordon in 1967 (Figure 1).
•Characterized by rigidity in axial, then limb muscles, co-contracture of both agonist and 
antagonist muscles, and superimposed muscle spasms.
•Rigidity and sudden spasms increase risk of falling.
•Associated anxiety and task-specific phobias; often misdiagnosed as psychological disorder.
•EMG demonstrates continuous motor unit activity at rest in both agonist and antagonist 
muscles; reduced EMG activity and rigidity when a patient is given diazepam (GABA agonist) is 
often used by clinicians to confirm the diagnosis.
•The diagnosis is one of exclusion, with normal strength and without dystonia, extrapyramidal 
or pyramidal tract signs.
PATHOGENESIS
•Considered autoimmune disease, associated with thyroiditis, Type 1 DM, pernicious anemia.
•Solimena first discovered antibodies to Glutamic Acid Decarboxylase (GAD) in 1988, which 
provided the first – and most commonly recognized – mechanism for the disease.
•GAD, found in 85% of those with SPS, is an essential enzyme in the conversion of glutamate 
to GABA, the major inhibitory neurotransmitter in skeletal muscle.
•Newly discovered antibodies, including Anti-GABARAP (65%), Anti-amphiphysin (5%), and 
Anti-gephyrin, suggest that SPS could also be a disorder of GABA transmission (Figure 2).
•5% of SPS represents a paraneoplastic syndrome and warrants suspicion of malignancy.
TREATMENT
THERAPIES
•Physical and occupational therapies can improve mobilization and balance.
•Psychological counseling can reduce anxiety and avoidance behavior.
PHARMOCLOGIC
Centrally acting
•Benzodiazepines are GABA enhancing drugs and considered the first-line treatment; 
Large doses (up to 200mg/day) are often needed with limitation of sedation.
•Antispastics such as baclofen (a GABA agonist), tizanidine (central α-agonist), and 
botulinum toxin (inhibitor of acetylcholine release) are second-line agents.
•Antiepileptics have also been used, including vigabatrin (GABA-transaminase inhibitor), 
gabapentin (similar structure to GABA), valproate (augments GABA transmission), and 
tiagabine (blocks GABA reuptake).
•Immunomodulators such as IVIG, plasmapheresis, and corticosteroids are gaining popularity 
but have limited evidence.
Peripherally acting 
•Dantrolene is a peripherally acting agent for treatment of spasticity and rigidity; it dissociates 
excitation-contraction coupling and blocks release of calcium from sarcoplasmic reticulum.
•Although its potential use is considered in SPS literature, there are no clinical trials.
•Recommended dosage at 200-400mg/day; side effects include diarrhea and hepatotoxicity.
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